Intravenous Immunoglobulin for Acute Intracranial Hemorrhage

• Status: Unknown status
• Trial end date: 2018-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This pilot study aims to investigate whether intravenous immunoglobulin is safe and effective in alleviating perihematomal edema and neurologic deficits in patients with intracranial hemorrhage.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wei Wang
• Treatments: Antibodies; gamma-Globulins; Immunoglobulins; Immunoglobulins, Intravenous; Rho(D) Immune Globulin

Criteria

Inclusion Criteria:

1. The first-ever primary supratentorial intracerebral basal ganglia hemorrhage 5-30ml.

2. 18-80 years old.

3. No longer than 72 hours from the acute ICH to medication.

4. Glasgow Coma Score ≥8.

Exclusion Criteria:

1. Occurrences of secondary intracerebral hemorrhage.

2. Significant past history of disability, modified Rankin Scale（mRS）≥1.

3. Currently taking antitumor drugs, immunosuppressive drugs, or immunomodulatory therapy.

4. Patients with pregnancy, Severe infection, severe heart dysfunction or renal and hepatic injuries.

5. Patients with contraindications for immunoglobulin.